Work Here?
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
New Haven, Connecticut
Founded
2013
Arvinas develops therapies aimed at treating serious diseases caused by harmful proteins. Their main product, PROTAC® protein degraders, works by using the body's natural system to eliminate these proteins selectively. This approach allows for targeted treatment of conditions like cancer and neurodegenerative disorders. Unlike many other biopharmaceutical companies, Arvinas focuses specifically on protein degradation, which sets them apart in the biotechnology field. Their goal is to enhance patient outcomes by creating effective therapies that tackle the root causes of diseases.
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$585.9M
Above
Industry Average
Funded Over
5 Rounds
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival –– Vepdegestrant is the first PROTAC degrader to demonstrate clinical benefitin a Phase 3 trial –NEW HAVEN, Conn. and NEW YORK, March 11, 2025 – Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy. These are the first pivotal data for vepdegestrant, a potential first-in-class investigational oral PROteolysis TArgeting Chimera (PROTAC) ER degrader.The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m) population, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to fulvestrant. The results exceeded the pre-specified target hazard ratio of 0.60 in the ESR1m population
In a corporate update, Arvinas announced the appointment of Alex Santini as interim Chief Commercial Officer, effective January 17, 2025.
Arvinas said it will also add 1,500 square feet of space at 5 Science Park for a total of 64,000 square feet.
Arvinas appoints Andrew Saik as CFO with equity incentives.
Arvinas Inc.Ian Taylor, Ph.D.President of Research and Development at Arvinas, Inc.Angela Cacace, Ph.D.Chief Scientific Officer at Arvinas, Inc.NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced Ian Taylor, Ph.D. has been promoted to President of Research and Development and Angela Cacace, Ph.D. has also been promoted and will succeed Dr. Taylor as Chief Scientific Officer of the company. Dr
Find jobs on Simplify and start your career today
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
New Haven, Connecticut
Founded
2013
Find jobs on Simplify and start your career today